含硼替佐米的诱导治疗、大剂量美法仑和来那度胺维持治疗用于70岁及以下多发性骨髓瘤患者
GMMG-MM5试验纳入601例18至70岁新诊断多发性骨髓瘤患者,按年龄分为≤60岁(S1,n=353)、61-65岁(S2,n=107)和66-70岁(S3,n=141)三组,均接受含硼替佐米诱导治疗、大剂量美法仑200 mg/m²(MEL200)联合自体造血干细胞移植(ASCT)、巩固治疗及来那度胺维持治疗。三组治疗依从性相似,S2和S3组总体毒性高于S1组,但无进展生存、总生存、至进展时间和非复发死亡率均无差异。
要点
- 66-70岁患者接受含硼替佐米诱导、MEL200/ASCT及来那度胺维持治疗,生存结局与≤60岁和61-65岁组无差异。
- S2和S3组总体毒性高于S1组:任何不良事件S1 81.7% vs S2 90.7% vs S3 87.2%(p=0.05),任何严重不良事件S1 41.8% vs S2 56.5% vs S3 68.1%(p<0.001)。
- 三组治疗依从性相似,无进展生存(log-rank p=0.73)、总生存(log-rank p=0.54)、至进展时间(Gray's p=0.83)和非复发死亡率(Gray's p=0.25)均无差异。
核心结论
- 作者认为,含硼替佐米诱导治疗、MEL200/ASCT、来那度胺巩固和维持的强化 upfront 治疗应应用于适合移植的70岁及以下多发性骨髓瘤患者。
研究设计与样本
- GMMG-MM5试验纳入601例18至70岁新诊断多发性骨髓瘤患者,按年龄分为≤60岁(S1,n=353)、61-65岁(S2,n=107)和66-70岁(S3,n=141)三组进行分析。
- 治疗方案包括含硼替佐米的诱导治疗、MEL200/ASCT、巩固治疗和来那度胺维持治疗。
主要发现
- 三组治疗依从性相似。
- 所有治疗阶段总体毒性S2和S3组高于S1组:任何不良事件S1 81.7% vs S2 90.7% vs S3 87.2%(p=0.05),任何严重不良事件S1 41.8% vs S2 56.5% vs S3 68.1%(p<0.001)。
- 无进展生存(log-rank p=0.73)、总生存(log-rank p=0.54)、至进展时间(Gray's p=0.83)和非复发死亡率(Gray's p=0.25)在三组间均无差异。
临床怎么用
- 作者认为,含硼替佐米诱导治疗、MEL200/ASCT、来那度胺巩固和维持的强化 upfront 治疗应应用于适合移植的70岁及以下多发性骨髓瘤患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Intensive upfront therapy in newly-diagnosed multiple myeloma (MM) including induction therapy (IT), high-dose melphalan (MEL200), and autologous blood stem cell transplantation (ASCT) followed by consolidation and/or maintenance is mostly restricted to patients up to 65 years of age. Prospective phase III trial data in the era of novel agents for patients up to 70 years of age are not available. The GMMG-MM5 trial included 601 patients between 18 and 70 years of age, divided in three groups for the present analysis: ≤60 years (S1, n = 353), 61-65 years (S2, n = 107) and 66-70 years (S3, n = 141). Treatment consisted of a bortezomib-containing IT, MEL200/ASCT, consolidation, and maintenance with lenalidomide. Adherence to treatment was similar among patients of the three age groups. Overall toxicity during all treatment phases was increased in S2 and S3 compared to S1 (any adverse event/any serious adverse event: S1:81.7/41.8% vs. S2:90.7/56.5% vs. S3:87.2/68.1%, p = 0.05/<0.001). With respect to progression-free survival (log-rank p = 0.73), overall survival (log-rank p = 0.54) as well as time-to-progression (Gray's p = 0.83) and non-relapse mortality (Gray's p = 0.25), no differences were found between the three age groups. Our results imply that an intensive upfront therapy with a bortezomib-containing IT, MEL200/ASCT, lenalidomide consolidation, and maintenance should be applied to transplant-eligible MM patients up to 70 years of age.
引用
- Mai EK, Miah K, Bertsch U, et al. Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age. Leukemia. 2020. PMID: 32684633. doi:10.1038/s41375-020-0976-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。